Isosorbideのメニエール病に対する効果に関する臨床的検討

DOI

書誌事項

タイトル別名
  • Clinical Study of Isosorbide on Meniere's Disease
  • Inter-group Comparative Study with Betahistine Mesylate by Multi-centered Double-blind Trial
  • 多施設二重盲検法によるBetahistine Mesylateとの群間比較

抄録

Clinical effect of Isosorbide (ISO) was studied in patients with Meniere's disease from their subjective symptoms and objective findings by multi-centered double-blind trial with Betahistine Mesylate (BM) as a reference drug. 1) Global improvement rating: ISO-treated group was more superior than BM-treated group in 2 weeks and 4 weeks after administration with a statistically significant difference (P<0.05) in Wilcoxon test when statistical analysis was made based on the judgement by investigators, however, there was no statistically significant difference between both groups when analyzed based on the judgement by the Committee. 2) Utility rate: Upon the judgement by investigators, ISO-treated group was more superior than BM-treated group in 2 weeks and 4 weeks after administration with a tendency of statistical difference in Wilcoxon test, however, there was no statistically significant difference between both groups upon the judgement by the Committee. 3) Side effect, clinical laboratory test and safety rate: There was no particular difference between both groups. From the above results, it was concluded that ISO was an effective and useful drug for Meniere's disease.

収録刊行物

  • 耳鼻と臨床

    耳鼻と臨床 32 (1), 44-92, 1986-01-20

    JIBI TO RINSHO KAI

キーワード

詳細情報 詳細情報について

  • CRID
    1390282680476098560
  • NII論文ID
    130004403124
  • DOI
    10.11334/jibi1954.32.1_44
  • ISSN
    04477227
  • 本文言語コード
    ja
  • データソース種別
    • JaLC
    • CiNii Articles
  • 抄録ライセンスフラグ
    使用不可

問題の指摘

ページトップへ